Chemistry:Saredutant
From HandWiki
Short description: Chemical compound
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C31H35Cl2N3O2 |
| Molar mass | 552.54 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist.[1] It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.[2]
See also
- GR-159,897
- Ibodutant
- Nepadutant
References
- ↑ "ACS chemical neuroscience molecule spotlight on Saredutant". ACS Chemical Neuroscience 1 (10): 653–4. October 2010. doi:10.1021/cn100061r. PMID 22776916.
- ↑ "Letter to the stockholders of Sanofi-Aventis". May 2009. http://www.sanofi-aventis.com/binaries/Lettre18_FR_Web_acc_tcm29-25341.pdf.

